Gastroenterology & Hepatology Clinical Trials

Statistical methods in gastroenterology & hepatology trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All gastroenterology & hepatology trials

642 results

• Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett’s Esophagus Compared With Standard Endoscopy: Complete Statistical AnalysisIndependent statistical analysis of Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 100NCT02066233
• Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers: Complete Statistical AnalysisIndependent statistical analysis of Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase NAResults postedn = 101NCT02551744
• PULSIndependent statistical analysis of Efficacy of Pantoprazole in Patients Older Than 12 Years With Reflux Associated Sleep Disorders (PULS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase NAResults postedn = 8,616NCT00562094
• QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer: Complete Statistical AnalysisIndependent statistical analysis of QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 3NCT03127098
• Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD): Complete Statistical AnalysisIndependent statistical analysis of Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD): primary endpoint results, effect estimate with…Phase 3Results postedn = 1,069NCT00658775
• RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment: Complete Statistical AnalysisIndependent statistical analysis of RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 54NCT00729482
• Radial Reload Laparoscopic LAR Case Series: Complete Statistical AnalysisIndependent statistical analysis of Radial Reload Laparoscopic LAR Case Series: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01706822).Phase 4Results postedn = 8NCT01706822
• RAFAELOCALIndependent statistical analysis of Evaluation of the Value of Perianal Infiltration During Thermodestruction of Haemorrhoidal Disease by Radiofrequency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 4Results postedn = 134NCT05519189
• Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC): Complete Statistical AnalysisIndependent statistical analysis of Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 1/2Results postedn = 14NCT00862082
• Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy: Complete Statistical AnalysisIndependent statistical analysis of Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 45NCT00746395
• RAPIDAIndependent statistical analysis of Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 100NCT02148718
• RE-CHUTIndependent statistical analysis of Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed): primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 97NCT00725842
• Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO: Complete Statistical AnalysisIndependent statistical analysis of Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 4Results postedn = 200NCT02461745
• Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis: Complete Statistical AnalysisIndependent statistical analysis of Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 107NCT01986686
• RELEASEIndependent statistical analysis of PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 2Results postedn = 41NCT04099888
• RELIEFIndependent statistical analysis of LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase NAResults postedn = 30NCT02429830
• Remicade Safety Line (Crohn’s Disease)(Study P03288)(COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00818272).Phase NAResults postedn = 148NCT00818272
• remifentanilIndependent statistical analysis of Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01693185).Phase 4Results postedn = 60NCT01693185
• Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors: Complete Statistical AnalysisIndependent statistical analysis of Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 11NCT03627299
• RESPIREIndependent statistical analysis of Evaluating Smoking Cessation Protocols in Cancer Patients: NRT, MI, CBT or Hypnotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 21NCT04899492
• RestorAATion-1Independent statistical analysis of A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1): primary endpoint results, effect estimate with confidence…Phase 1Results postedn = 47NCT06186492
• ROCKETIndependent statistical analysis of A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 2Results postedn = 62NCT02096354
• SIGNATUREIndependent statistical analysis of LDE225 for Patients With PTCH1 or SMO Mutated Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02002689).Phase 2Results postedn = 10NCT02002689
• SKYLINEIndependent statistical analysis of Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 61NCT06104319
• SOFTIndependent statistical analysis of Bladder Drainage During Labor: A Randomized Controlled Study of Obstetric Foley Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 139NCT00959920
• SPRINT-2Independent statistical analysis of SPRINT-2, a randomized phase 3 trial of boceprevir plus peginterferon alfa-2b and ribavirin in previously untreated adults with chronic hepatitis C genotype 1.Phase 3Results postedn = 1,472NCT00705432
• steroids/NECIndependent statistical analysis of Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 2NCT01156480
• SWARM-PaIndependent statistical analysis of Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis: primary endpoint results, effect estimate with confidence…Phase 1/2Results postedn = 29NCT04596319
• TK112690Independent statistical analysis of Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 22NCT04046250
• TOPASIndependent statistical analysis of Evaluation of Outcomes of Restoring Pelvic Floor Support With TOPAS in Women With Moderate Fecal Incontinence Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 1/2Results postedn = 29NCT00565136
• TOPAZIndependent statistical analysis of Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.: primary endpoint results, effect estimate with confidence interval, sample-size…Phase NAResults postedn = 320NCT02754661
• TOPAZ-1Independent statistical analysis of Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 810NCT03875235
• TOPAZ-IIndependent statistical analysis of A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV)…Phase 3Results postedn = 1,596NCT02219490
• TURQUOISE-CPBIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4…Phase 3Results postedn = 36NCT02219477
• UGIH09067Independent statistical analysis of Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 2Results postedn = 31NCT01308840
• UNIFIIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis: primary endpoint results, effect estimate…Phase 3Results postedn = 961NCT02407236
• VALUEIndependent statistical analysis of Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel…Phase NAResults postedn = 427NCT02750800
• VERITASIndependent statistical analysis of Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary: primary endpoint…Phase NAResults postedn = 244NCT02636608
• VIVID-1Independent statistical analysis of A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03926130).Phase 3Results postedn = 1,158NCT03926130
• X-TRAPIndependent statistical analysis of Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 63NCT01661972
• YES-PIndependent statistical analysis of Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…Phase 3Results postedn = 36NCT01887717
• ZEAL UNLOCKIndependent statistical analysis of A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 73NCT06269484

← All therapeutic areas